ライフサイエンスコーパス: neuromyelitis optica

1 itudinal myelopathy outside of BD, including neuromyelitis optica.

2 the neuroinflammatory demyelinating disease neuromyelitis optica.

3 a postrema may be a first point of attack in neuromyelitis optica.

4 ith multiple sclerosis and optic neuritis in neuromyelitis optica.

5 demyelination, and necrosis that is seen in neuromyelitis optica.

6 s distinguish it from multiple sclerosis and neuromyelitis optica.

7 nostaining is detectable in early lesions of neuromyelitis optica.

8 ncorporated into new diagnostic criteria for neuromyelitis optica.

9 l multiple sclerosis seems to be the same as neuromyelitis optica.

10 cephalomyelitis, Guillain-Barre syndrome and neuromyelitis optica.

11 toimmunity, including multiple sclerosis and neuromyelitis optica.

12 concurrent AQP4 antibodies had conversion to neuromyelitis optica.

13 ents, none of whom had multiple sclerosis or neuromyelitis optica.

14 be recognized as rare presenting features of neuromyelitis optica.

15 of CNS inflammation and astrocytic injury in neuromyelitis optica.

16 le, 207 clinically isolated syndrome and six neuromyelitis optica.

17 Of the 48 controls with neuromyelitis optica, 37 (77%) had AQP4 antibodies, 4 (8

18 many recurrent cases who also have myelitis (neuromyelitis optica) a serum antibody to aquaporin-4 wa

19 oantibodies were discovered in patients with neuromyelitis optica, a demyelinating disease, and are n

20 this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS.

21 ous system inflammatory disorders, including neuromyelitis optica, acute disseminated encephalomyelit

22 ary tests, such as diagnostic antibodies for neuromyelitis optica, allows better phenotyping of the h

23 Neuromyelitis optica (also known as Devic's disease) is

24 nts with optic neuritis, multiple sclerosis, neuromyelitis optica, Alzheimer disease, and Parkinson d

25 imaging of the retina in multiple sclerosis, neuromyelitis optica, Alzheimer disease, and Parkinson d

26 We review recent advances in neuromyelitis optica, an idiopathic inflammatory demyeli

27 were 73% (95% CI 60-86) and 91% (79-100) for neuromyelitis optica and 58% (30-86) and 100% (66-100) f

28 all patient groups investigated, those with neuromyelitis optica and a history of optic neuritis exh

29 lassical multiple sclerosis and both Devic's neuromyelitis optica and acute disseminated encephalomye

30 aware of the uncommon presenting features of neuromyelitis optica and associated autoimmune condition

31 NMO-IgG is a specific marker autoantibody of neuromyelitis optica and binds at or near the blood-brai

32 mmunoglobulin G, is strongly associated with neuromyelitis optica and identifies patients with severe

33 Objective Neuromyelitis optica and its spectrum disorders (NMOSD)

34 ple sclerosis (n = 31) recruited from Oxford neuromyelitis optica and multiple sclerosis clinical ser

35 Neuromyelitis optica and neuromyelitis optica spectrum d

36 to be explored further in future prospective neuromyelitis optica and neuromyelitis optica spectrum d

37 Previous clinical neuromyelitis optica and neuromyelitis optica spectrum d

38 rtant implications for interpreting clinical neuromyelitis optica and neuromyelitis optica spectrum d

39 euromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple

40 sion, facilitated the ability to distinguish neuromyelitis optica and related syndromes from typical

41 reproduces the key histological features of neuromyelitis optica and that aquaporin-4 is necessary a

42 7% acute disseminated encephalomyelitis, 7% neuromyelitis optica), and 91% received treatment (85% s

43 ls (30 healthy individuals, 48 patients with neuromyelitis optica, and 64 patients with multiple scle

44 ses such as systemic lupus erythematosus and neuromyelitis optica, and can lead to transient or perma

45 sms of acute disseminated encephalomyelitis, neuromyelitis optica, and classical multiple sclerosis.

46 tion and inflammation in multiple sclerosis, neuromyelitis optica, and in experimental autoimmune enc

47 immunity is prominent in multiple sclerosis, neuromyelitis optica, and the paraneoplastic syndromes w

48 P4 was labeled with a monoclonal recombinant neuromyelitis optica autoantibody.

49 whether patients with multiple sclerosis or neuromyelitis optica develop retinal neuronal layer path

50 after vomiting onset), 7 patients fulfilled neuromyelitis optica diagnostic criteria.

51 Devic's neuromyelitis optica (DNO) is a demyelinating syndrome t

52 ine]) supported the alternative diagnosis of neuromyelitis optica for 2 patients as seropositive by b

53 body marker (NMO-IgG) further differentiates neuromyelitis optica from multiple sclerosis and has hel

54 unoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis.

55 It distinguishes neuromyelitis optica from multiple sclerosis.

56 ologic, and immunologic features distinguish neuromyelitis optica from other severe cases of multiple

57 Neuromyelitis optica has a worldwide distribution, poor

58 The recent identification of neuromyelitis optica-IgG, a novel marker of neuromyeliti

59 e-based assays using sera from patients with neuromyelitis optica, immune mouse serum, and Abs raised

60 ecently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which d

61 A specific serum biomarker, neuromyelitis optica immunoglobulin G, is strongly assoc

62 Neuromyelitis optica-immunoglobulin G (NMO-IgG) binds to

63 Neuromyelitis optica is a rare neurological autoimmune d

64 Neuromyelitis optica is an inflammatory demyelinating di

65 Neuromyelitis optica is an inflammatory demyelinating di

66 Neuromyelitis optica is an inflammatory demyelinating di

67 Neuromyelitis optica is associated with severe neurodisa

68 The neuroinflammatory demyelinating disease neuromyelitis optica is marked by pathogenic autoantibod

69 Neuromyelitis optica is the most severe of these disorde

70 water channel aquaporin-4, which is lost in neuromyelitis optica lesions.

71 damaged, and how circulating AQP4-IgG enters neuromyelitis optica lesions.

72 ly the disease pattern does not resemble the neuromyelitis optica-like disease observed in mice beari

73 tica patients with human complement produced neuromyelitis optica-like lesions in mice.

74 e autoimmune response against aquaporin-4 in neuromyelitis optica may be triggered by infection-induc

75 Most patients with neuromyelitis optica (NMO) and many with NMO spectrum di

76 Neuromyelitis optica (NMO) and multiple sclerosis (MS) a

77 b was detected in three; two presenting with neuromyelitis optica (NMO) and one with isolated optic n

78 quaporin 4 (AQP4)-specific autoantibodies in neuromyelitis optica (NMO) are immunoglobulin (Ig)G1, a

79 Neuromyelitis optica (NMO) attacks often are severe, are

80 P4) water channel-specific IgG distinguishes neuromyelitis optica (NMO) from multiple sclerosis and c

81 Neuromyelitis optica (NMO) has been described as a disea

82 Neuromyelitis optica (NMO) has long been considered as a

83 75%) were positive and 12 (25%) negative for neuromyelitis optica (NMO) IgG (per IIF of serial serum

84 We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the ini

85 Neuromyelitis optica (NMO) is a chronic inflammatory dis

86 Neuromyelitis optica (NMO) is a neuroinflammatory diseas

87 Neuromyelitis Optica (NMO) is a severe and rare inflamma

88 Neuromyelitis optica (NMO) is a severe autoimmune inflam

89 Neuromyelitis optica (NMO) is a severe inflammatory CNS

90 Neuromyelitis optica (NMO) is an autoimmune disease of t

91 Neuromyelitis optica (NMO) is an autoimmune disease of t

92 Neuromyelitis optica (NMO) is an inflammatory demyelinat

93 Neuromyelitis optica (NMO) is an inflammatory demyelinat

94 Neuromyelitis optica (NMO) is an inflammatory demyelinat

95 Neuromyelitis optica (NMO) is an inflammatory demyelinat

96 Neuromyelitis optica (NMO) is an inflammatory demyelinat

97 Neuromyelitis optica (NMO) is an inflammatory demyelinat

98 Neuromyelitis optica (NMO) is an inflammatory demyelinat

99 Neuromyelitis optica (NMO) is an inflammatory demyelinat

100 Neuromyelitis optica (NMO) is an inflammatory demyelinat

101 Neuromyelitis optica (NMO) is an inflammatory disease of

102 Neuromyelitis optica (NMO) is caused by binding of patho

103 Neuromyelitis optica (NMO) is characterized by disabling

104 Neuromyelitis optica (NMO) is characterized by the prese

105 Aquaporin 4 antibody-negative neuromyelitis optica (NMO) is rare when good assays are

106 rosis is a prominent pathological feature of neuromyelitis optica (NMO) lesions and is clinically rel

107 Coded samples from patients with neuromyelitis optica (NMO) or NMOSD (101) and controls (

108 in-4 (AQP4)-specific T cells are expanded in neuromyelitis optica (NMO) patients and exhibit Th17 pol

109 The serum of most neuromyelitis optica (NMO) patients contains autoantibod

110 T cells from neuromyelitis optica (NMO) patients, which recognize the

111 epeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvem

112 ceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4

113 segments) is considered noncharacteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs).

114 rosis (MS), anti-aquaporin-4 (AQP4)-negative neuromyelitis optica (NMO), and chronic relapsing inflam

115 emblance the disease shows pathologically to neuromyelitis optica (NMO), including that demyelination

116 ere divided in 5 different groups: controls, neuromyelitis optica (NMO), longitudinally extensive tra

117 unified by detection of the serum biomarker neuromyelitis optica (NMO)-IgG.

118 Neuromyelitis optica (NMO)-immunoglobulin G (IgG) is a c

119 exacerbates MS, and it consistently worsens neuromyelitis optica (NMO).

120 rin-4 (AQP4) are thought to be pathogenic in neuromyelitis optica (NMO).

121 y specific for the neuroinflammatory disease neuromyelitis optica (NMO).

122 s and an update on the current management of neuromyelitis optica (NMO).

123 diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO).

124 ntal autoimmune encephalomyelitis (EAE), and neuromyelitis optica (NMO).

125 has come into focus for its association with neuromyelitis optica (NMO).

126 ptic neuritis is a cardinal manifestation of neuromyelitis optica (NMO).

127 ant in inflammatory demyelinating lesions in neuromyelitis optica (NMO).

128 nerve and spinal cord pathologic changes in neuromyelitis optica (NMO).

129 Devic's disease [neuromyelitis optica (NMO)] is an idiopathic inflammator

130 sessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyeli

131 sitive cases identified incidentally, 12 had neuromyelitis optica or a high-risk syndrome for the dis

132 amples from 102 North American patients with neuromyelitis optica or with syndromes that suggest high

133 nction were more likely to meet criteria for neuromyelitis optica (P = 0.04) and were also more likel

134 ly in 98 multiple sclerosis participants, 22 neuromyelitis optica participants and 72 healthy control

135 es, mice injected with immunoglobulin G from neuromyelitis optica patients and human complement into

136 n 12 h of co-injecting immunoglobulin G from neuromyelitis optica patients and human complement, ther

137 Immunoglobulin G from neuromyelitis optica patients did not activate mouse com

138 In our mouse model, immunoglobulin G from neuromyelitis optica patients does not require pre-exist

139 lin G from aquaporin-4-autoantibody-positive neuromyelitis optica patients has the potential to damag

140 ently been reported that immunoglobulin from neuromyelitis optica patients injected peripherally does

141 utely ill multiple sclerosis patient and two neuromyelitis optica patients revealed instances of infi

142 ary and sufficient for immunoglobulin G from neuromyelitis optica patients to exert its effect.

143 wever, co-injection of immunoglobulin G from neuromyelitis optica patients with human complement prod

144 e that co-injection of immunoglobulin G from neuromyelitis optica patients with human complement repr

145 mice that received immunoglobulin G from non-neuromyelitis optica patients with human complement, or

146 ull mice that received immunoglobulin G from neuromyelitis optica patients with human complement.

147 were unchanged in primary progressive MS and neuromyelitis optica patients.

148 gut of patients with multiple sclerosis and neuromyelitis optica provides evidence of communication

149 uropathy, optic neuritis/multiple sclerosis, neuromyelitis optica, pseudotumor cerebri, migraine, opt

150 ng diseases (i.e., multiple sclerosis versus neuromyelitis optica) represents distinct syndromes.

151 t AQP4-IgG is involved in the development of neuromyelitis optica revolutionised our understanding of

152 tity of autoimmune AQP4 myopathy extends the neuromyelitis optica spectrum beyond the central nervous

153 ics of ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorder (NMOSD) myelitis

154 is a common and debilitating consequence of neuromyelitis optica spectrum disorder (NMOSD) myelitis,

155 Reports of neuromyelitis optica spectrum disorder (NMOSD) occurring

156 Patients with MOG-IgG had neuromyelitis optica spectrum disorder (NMOSD, n=10), id

157 ses in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute dissemi

158 e non-Hispanic patients with MS reveals that neuromyelitis optica spectrum disorder is rarely misdiag

159 Previous clinical neuromyelitis optica and neuromyelitis optica spectrum disorder studies have incl

160 terpreting clinical neuromyelitis optica and neuromyelitis optica spectrum disorder studies, since cl

161 future prospective neuromyelitis optica and neuromyelitis optica spectrum disorder studies.

162 These syndromes include neuromyelitis optica spectrum disorder, acute disseminat

163 -seropositive, aged at least 18 years, had a neuromyelitis optica spectrum disorder, and had at least

164 n-4 were positive, leading to a diagnosis of neuromyelitis optica spectrum disorder.

165 neuromyelitis optica-IgG, a novel marker of neuromyelitis optica spectrum disorders (including longi

166 Neuromyelitis optica spectrum disorders (NMOSD) can pres

167 uaporin (AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis optica spectrum disorders (NMOSD).

168 Importance: Neuromyelitis optica spectrum disorders (NMOSDs) are aut

169 We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Aust

170 ng atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and relapsing ac

171 Neuromyelitis optica and neuromyelitis optica spectrum disorders have been recent

172 ffecting humans, such as multiple sclerosis, neuromyelitis optica spectrum disorders, Parkinson disea

173 In multiple sclerosis and neuromyelitis optica spectrum disorders, T cells destroy

174 organs beyond the central nervous system in neuromyelitis optica spectrum disorders.

175 at neutralises the complement protein C5--in neuromyelitis optica spectrum disorders.

176 ability measures in patients with aggressive neuromyelitis optica spectrum disorders.

177 ng for this biomarker has suggested that the neuromyelitis optica spectrum is broader than previously

178 ultiple sclerosis and has helped to define a neuromyelitis optica spectrum of disorders.

179 The relation of neuromyelitis optica to optic-spinal multiple sclerosis

180 Its presence and specificity for neuromyelitis optica was confirmed in diverse population

181 ce 2005) whose initial presenting symptom of neuromyelitis optica was intractable vomiting.

182 Patients with neuromyelitis optica who have aquaporin-4 antibodies are

183 exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for ratio

184 This report highlights the association of neuromyelitis optica with dermatitis herpetiformis, whic

185 ith multiple sclerosis and participants with neuromyelitis optica, with and without a history of opti

186 articipants with multiple sclerosis and with neuromyelitis optica without a history of optic neuritis